FFO
ZNTL icon

Fortitude Family Office’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Fortitude Family Office’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01K Hold
209
– – ﹤0.01% 1748
2026
Q1 		$489 Buy
+209
New +$540 ﹤0.01% 1737

Other funds holding ZNTL

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return
SCP
Sivia Capital Partners Mill Valley, California $822M AUM 48.82% 1-Year Est. Return
ECM
Evergreen Capital Management Bellevue, Washington $5.7B AUM 32.06% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Fortitude Family Office's ZNTL Position: Q2 2026 in Review

Fortitude Family Office held its Zentalis Pharmaceuticals (ZNTL) position steady in Q2 2026 at 209 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #1748.

Fortitude Family Office first reported a position in ZNTL in Q1 2026 and has held it in 2 quarters since. 9 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Fortitude Family Office held 209 shares of Zentalis Pharmaceuticals worth $1.01K as of Q2 2026.
  • Fortitude Family Office left its Zentalis Pharmaceuticals share count unchanged in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1748 holding.
  • Fortitude Family Office first reported a position in Zentalis Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 9 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.